Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985824 | 0.92 | KMT2A (0.51) | TDP1CYP1A2HTR1AKMT2AHTT | |
| SCHEMBL1711871 | 0.82 | TDP1 (0.48) | TDP1CYP1A2HTR1AMAPTPHGDH | |
| SCHEMBL196592 | 0.81 | TDP1 (0.52) | TDP1CYP1A2MAPTKMT2AHTT | |
| SCHEMBL6044018 | 0.79 | TDP1 (0.50) | TDP1CYP1A2HTR1AMAPTPHGDH | |
| SCHEMBL6043670 | 0.79 | ATM (0.48) | TDP1CYP1A2HTR1AKMT2AHTT | |
| SCHEMBL799201 | 0.78 | TDP1 (0.54) | TDP1CYP1A2HTR1AMAPTPHGDH | |
| SCHEMBL802314 | 0.78 | CYP1A2 (0.54) | TDP1CYP1A2HTR1AMAPTPHGDH | |
| SCHEMBL1385227 | 0.78 | TDP1 (0.54) | TDP1CYP1A2HTR1AMAPTPHGDH | |
| SCHEMBL772617 | 0.77 | HSD11B1 (0.51) | KMT2A | |
| SCHEMBL206420 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664027-B1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-12-30 | — | — | EP | claimed |
| JP-4338974-B2 | — | — | 2009-10-07 | — | — | JP | claimed |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | claimed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | claimed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | claimed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | claimed |
| EP-1664023-B1 | SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-08-13 | — | — | EP | claimed |
| US-7390820-B2 | Substituted quinolinone derivatives and methods of use | AMGEN INC. (US) | 2008-06-24 | — | — | US | claimed |
| EP-1572678-A4 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARM INC (US) | 2008-05-07 | — | — | EP | claimed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | claimed |
| EP-0899261-A1 | Optical active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 1999-03-03 | — | — | EP | claimed |
| US-5693619-A | ENZYME INHIBITORS; ADMINISTERED TO TREAT CONGESTIVE HEART FAILURE AND HYPERTENSION | BOEHRINGER INGELHEIM (CANADA), LTD. (CA) | 1997-12-02 | — | — | US | claimed |
| EP-0589446-B1 | N-(Hydroxyethyl)butanediamide derivatives as renin inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 1997-09-03 | — | — | EP | claimed |
| EP-0589445-B1 | Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1997-01-15 | — | — | EP | claimed |
| US-5541163-A | HYPOTENSIVE AGENTS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1996-07-30 | — | — | US | claimed |
| WO-1994007846-A1 | RENIN INHIBITING N-(2-AMINO-2-OXOETHYL)BUTANEDIAMIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-04-14 | — | — | WO | claimed |
| WO-1994007845-A1 | N-(HYDROXYETHYL)BUTANEDIAMIDE DERIVATIVES AS RENIN INHIBITORS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-04-14 | — | — | WO | claimed |
| EP-0589445-A1 | Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-03-30 | — | — | EP | claimed |
| EP-0589446-A1 | N-(Hydroxyethyl)butanediamide derivatives as renin inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-03-30 | — | — | EP | claimed |
| EP-0390693-B1 | THIOFORMAMIDE DERIVATIVES | RHONE-POULENC SANTE (FR) | 1993-08-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | TDP1 1360/4885CYP1A2 24/4885HTR1A 380/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | TDP1 611/4885CYP1A2 87/4885HTR1A 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.